RxDoctor Payments Data

Hung Ng, MD

Internal Medicine · New York, NYNPI 1487727475

Payments from drug & device makers

$1,587in general payments, 2019–2025

Across 76 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$662
  • Amgen$195
  • AstraZeneca$185
  • Gilead$175
  • GSK$120
  • Amarin Pharma, Inc.$89
  • plus $159 from 5 others

What the payments were for

  • Food & beverage$1,56699%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,587 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$56,689
Medicare patients
78
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl607$266,494
JanuviaSitagliptin Phosphate239$245,932
Diclofenac Epolamine114$178,636
JardianceEmpagliflozin137$150,455
ProliaDenosumab65$111,114
FarxigaDapagliflozin Propanediol43$61,489
EliquisApixaban32$39,135
XareltoRivaroxaban30$37,245
TrulicityDulaglutide31$30,981
VemlidyTenofovir Alafenamide21$30,441
RybelsusSemaglutide19$29,575
RestasisCyclosporine36$22,097
ShingrixVaricella-Zoster Ge/As01b/Pf93$18,096
EntrestoSacubitril/Valsartan11$15,450
TradjentaLinagliptin26$13,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Jentadueto$82$190,889202 claims
AmgenProlia$195$111,11465 claims
AstraZenecaFarxiga, Symbicort$185$68,47868 claims
PfizerEliquis$15$39,13532 claims
Johnson & JohnsonXarelto$12$37,24530 claims
Lilly USA, LLCTrulicity$13$30,98131 claims
GileadVemlidy$175$30,44121 claims
Novo NordiskRybelsus$662$29,57519 claims
GSKShingrix, Trelegy Ellipta$120$25,269104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →